Kinarus
ExitedKinarus develops differentiated medicines in areas of stress related inflammatory processes based on cross disease area target assessment.
Basel, Switzerlandwww.kinarus.com ↗
Total raised
€73M
€73,192,941
Funding rounds
2
Investors
2
distinct backers
Active since
2021-09
latest 2022-08
Funding by year
EUR raised per yearFunding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-08-22 | Debt | €21M | YA II PN | View deal → |
| 2021-09-16 | Other | €52M | Global Emerging Markets | View deal → |
Exit
Type
merger
Date
Apr 2024
Value
—
Acquiror
Curatis (Switzerland)
Investors
2Related news
- Kinarus secures CHF20 million to accelerate clinical developmentstartupticker.ch · 2022-08
- Kinarus secures CHF 57 millionstartupticker.ch · 2021-09
- startupticker.ch
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy